psmarketresearch1’s blog

All about market research update

Niemann–Pick Disease Therapeutics Pipeline Analysis - Collaboration, and Other Developments


Niemann-Pick Disease is a type of lipid storage disorder characterised by accumulation of fatty substances in organs such as spleen, liver, and brain, eventually causing cell death resulting in malfunctioning of major organ systems. Its pathogenesis involves deficiency of a lysosomal enzyme called acid sphingomyelinase, and is mainly caused by genetic mutation. Niemann-Pick disease is majorly prevalent in North America, South America, Europe, Africa, Asia, and Australia. There are three main types of Niemann-Pick Disease called Type A and B (Acid Sphingomyelinase Deficiency) and Niemann-Pick Disease Type C (NPC). Approximately 1,200 cases of NPA and NPB have been recorded, worldwide, with the majority being Type B or the intermediate form. Cure for Type A disease is yet to be found and researchers are continuously trying new possible treatments including enzyme replacement and gene therapy. For Type D, there is no effective treatment; however, few drugs are available for curing the nervous system symptoms of Type C disease.

Explore Report at:

In April 2017, Sucampo Pharmaceuticals acquired Vtesse Inc., including its clinical stage Niemann-Pick disease type C1 drug, VTS-270. However, the Vtesse team will continue the ongoing Phase IIb/III clinical trials for VTS-270. The trials are expected to readout in mid-2018 and the drug could reach the market as early as 2019. In March 2017, CTD Holdings, Inc. began recruitment for a Phase I EU clinical trials of Trappsol® cycloTM to be used for the treatment of Niemann-Pick Disease Type C. In addition to the EU study, CTD Holdings is planning to initiate Phase I clinical trials in the U.S. for evaluating intravenous administration of Trappsol® Cyclo™ in NPC patients. In June 2016, Orphazyme APS announced dosing of two patients with arimoclomol in the Phase 3 ‘AIDNPC’ Niemann-Pick Disease Type C clinical trial programme. For the study, Orphazyme is seeking approval for clinical trial applications with eight national competent authorities and ethics committees.

Request for Table of Content at:

The key market players having a therapeutic pipeline for Niemann-Pick disease include CTD Holdings, Inc., Sanofi Genzyme, Alexion Pharmaceuticals, Actelion Pharmaceuticals Ltd, Vtesse Inc., La Jolla Pharmaceutical Company, Merck & Co., Inc., Okklo Life Sciences BV, Orphazyme ApS and Aldagen Inc.